ArticleFuture science OA2016
Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.
Open access · goldAbstract read
In one paragraph
Article in Future science OA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 28% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Impact of molecular and clinical variables on survival outcome with immunotherapy for glioblastoma patients: A systematic review and meta-analysis.CNS neuroscience & therapeutics · 2022Pooled it
- Midkine and pleiotrophin in glioma: From mechanistic insights to therapeutic potential.Neoplasia (New York, N.Y.) · 2026Review
- Biomarkers for predicting immunotherapy response and resistance in glioblastoma.Frontiers in immunology · 2026Review
- Extracellular Matrix Components and Mechanosensing Pathways in Health and Disease.Biomolecules · 2024Review
- Biomarkers of immunotherapy in glioblastoma.Neuro-oncology practice · 2024Review
- Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status.Vaccines · 2024Review
- Review
- Proteoglycans: a common portal for SARS-CoV-2 and extracellular vesicle uptake.American journal of physiology. Cell physiology · 2023Review
- Next Steps for Immunotherapy in Glioblastoma.Cancers · 2022Review
- Vincetoxicum arnottianum modulates motility features and metastatic marker expression in pediatric rhabdomyosarcoma by stabilizing the actin cytoskeleton.BMC complementary medicine and therapies · 2021Article
- Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer.Biomolecules · 2021Review
- Molecular Characterization of Astrocytoma Progression Towards Secondary Glioblastomas Utilizing Patient-Matched Tumor Pairs.Cancers · 2020Article
- Proteoglycans as Therapeutic Targets in Brain Cancer.Frontiers in oncology · 2020Review
- Heparan Sulfate Proteoglycans in Human Colorectal Cancer.Analytical cellular pathology (Amsterdam) · 2018Review
- Proteoglycans-Biomarkers and Targets in Cancer Therapy.Frontiers in endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Satoshi TakashimaDepartment of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Yoshihiro OkaDepartment of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Immunopathology, Immunology Frontier Research Center (World Premier International Research Center), Osaka University, 3-1 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Immunopathology, Immunology Frontier Research Center (World Premier International Research Center), Osaka University, 3-1 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Fumihiro FujikiDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Soyoko MorimotoDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Hiroko NakajimaDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Yoshiki NakaeDepartment of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Hematology, Kitano Hospital, 2-4-10 Ohgimachi, Kita-ku, Osaka City, Osaka 530-8480, Japan; Department of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Hematology, Kitano Hospital, 2-4-10 Ohgimachi, Kita-ku, Osaka City, Osaka 530-8480, Japan.
Jun NakataDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Sumiyuki NishidaDepartment of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Naoki HosenDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Naoya TatsumiDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Kenji MizuguchiNational Institutes of Biomedical Innovation, Health & Nutrition 7-6-8 Saito-Asagi, Ibaraki City, Osaka 567-0085, Japan; National Institutes of Biomedical Innovation, Health & Nutrition 7-6-8 Saito-Asagi, Ibaraki City, Osaka 567-0085, Japan.
Naoya HashimotoDepartment of Neurosurgery, Kyoto Prefectural University Graduate Schoolof Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto City, Kyoto 602-8566, Japan; Department of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Neurosurgery, Kyoto Prefectural University Graduate Schoolof Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto City, Kyoto 602-8566, Japan; Department of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Yusuke OjiDepartment of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Akihiro TsuboiDepartment of Cancer Immunotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Atsushi KumanogohDepartment of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Immunopathology, Immunology Frontier Research Center (World Premier International Research Center), Osaka University, 3-1 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Immunopathology, Immunology Frontier Research Center (World Premier International Research Center), Osaka University, 3-1 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Haruo SugiyamaDepartment of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan; Department of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan.
Osaka University · JPKyoto Prefectural University of Medicine · JPNational Institute of Biomedical Innovation, Health and Nutrition · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn cancer immunotherapy, biomarkers are important for identification of responsive patients. This study was aimed to find biomarkers that predict clinical outcome of WT1 peptide vaccination. MATERIALS &
methodsCandidate genes that were expressed differentially between long- and short-term survivors were identified by cDNA microarray analysis of peripheral blood mononuclear cells that were extracted from 30 glioblastoma patients (discovery set) prior to vaccination and validated by quantitative RT-PCR using discovery set and different 23 patients (validation set).
results
conclusion
Indexed as
cancer immunotherapyDC-HILGBMglioblastoma multiformeimmune checkpoint inhibitormalignant gliomapeptide vaccineSDC-4Syndecan-4WT1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.